or Try an Advanced Search...

    Progressive Stocks List

    Symbol Grade Name % Change
    MIRM B Mirum Pharmaceuticals, Inc. -2.04
    ITT B ITT Corporation 0.00
    EXEL B Exelixis, Inc. -0.13
    CHX C ChampionX Corporation 2.12
    LRMR D Larimar Therapeutics, Inc. -1.32
    IGT F International Game Technology -0.11
    BIIB F Biogen Idec Inc. -0.06
    GLTO F Galecto, Inc. 0.58
    FULC F Fulcrum Therapeutics, Inc. 1.67
    View As Page of Charts
    Related Industries: Biotechnology Diversified Industrials Drug Manufacturers - Major Gambling Oil & Gas Equipment & Services
    Related Stock Lists: Biotechnology Medicine Cancer Disability Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Pump Acid Aerospace Components Aerospace Market Alcohol Alzheimer's Disease Artificial Lift Equipment Asset Integrity Management Ataxia Autoimmune Disorders Bearings Bile Acid Bingo Biology

    Related ETFs - A few ETFs which own one or more of the above listed Progressive stocks.

    Symbol Grade Name Weight
    PBE D PowerShares Dynamic Biotech & Genome 8.07
    FBT D First Trust Amex Biotech Index Fund 7.46
    BIS B ProShares UltraShort Nasdaq Biotechnology 6.85
    IDNA D iShares Genomics Immunology and Healthcare ETF 6.44
    BBP C BioShares Biotechnology Products Fund 5.82
    View all Progressive ETFs...
    Compare ETFs
    Compare BIS to IDNA Compare FBT to BBP Compare PBE to FBT

        Progressive Stocks Recent News

        Date Stock Title
        Nov 20 BIIB Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
        Nov 20 EXEL Zacks.com featured highlights Amazon, Maplebear, Exelixis and Doximity
        Nov 20 BIIB Biogen Inc. (BIIB): Among the Best Genomics Stocks to Buy Right Now
        Nov 19 BIIB Biogen, UCB release phase 3 data on lupus candidate dapirolizumab
        Nov 19 BIIB Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
        Nov 18 BIIB Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
        Nov 18 BIIB Needham downgrades Biogen on slow growth of Alzheimer's drug
        Nov 18 BIIB Biogen cut to hold by Needham on lack of catalysts, slow Leqembi sales
        Nov 18 BIIB Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™
        Nov 18 LRMR Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024
        Nov 18 ITT ITT Announces Participation at UBS Global Industrials & Transportation Conference 2024 on Dec. 4
        Nov 18 BIIB Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now?
        Nov 15 BIIB Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe
        Nov 15 CHX ChampionX declares $0.095 dividend
        Nov 15 MIRM Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results
        Nov 15 FULC Fulcrum Therapeutics Third Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.39 loss in 3Q 2023)
        Nov 15 CHX ChampionX Declares Quarterly Dividend
        Nov 14 IGT Everi Stockholders Approve Acquisition by Apollo Funds
        Nov 14 CHX ChampionX Wins Golden Peacock Award for Global Sustainability
        Nov 14 BIIB European committee takes a second look at Alzheimer's drug and now says it should be approved
        Related Industries: Biotechnology Diversified Industrials Drug Manufacturers - Major Gambling Oil & Gas Equipment & Services
        Related Stock Lists: Biotechnology Medicine Cancer Disability Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Pump Acid Aerospace Components Aerospace Market Alcohol Alzheimer's Disease Artificial Lift Equipment Asset Integrity Management Ataxia Autoimmune Disorders Bearings Bile Acid Bingo Biology
        Progressive

        Browse All Tags